{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Possibly Marketed Outside US
Source:
EBV/CFS Plus by Deseret Biologicals, Inc.
(2018)
Source URL:
First approved in 2018
Source:
EBV/CFS Plus by Deseret Biologicals, Inc.
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
21 CFR 333D
(2012)
Source URL:
First approved in 2012
Source:
21 CFR 333D
Source URL:
Class:
STRUCTURALLY DIVERSE